Amoxicillin/clavulanic acid-warfarin drug interaction: a randomized controlled trial.
作者： Qian Zhang , Guy Simoneau , Celine Verstuyft , Ludovic Drouet , Claire Bal dit Sollier
DOI: 10.1111/J.1365-2125.2010.03824.X
关键词:
摘要: WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Increased INR was previously observed in patients treated with warfarin and amoxicillin/clavulanic acid (amoxiclav) combination. To date, no prospective study has yet evaluated the effect of amoxiclav on therapy consequently, there are clear-cut conclusions or clear recommendations for clinicians. WHAT PAPER ADDS • We provided first systematic evaluation interaction between found that did not modify stable absence any infectious inflammatory syndrome, suggesting increase these may be attributable to a drug–drug interaction. AIMS investigate whether an exists oral anticoagulant therapy. METHODS In double-blind, cross-over, placebo-controlled study, 12 therapy, received 7 day regimen placebo. RESULTS The mean maximum 0.22 ± 0.3 vs. 0.24 0.6 placebo (P= 0.94). 7–day 1 factor II, R(–) S(–) plasma concentrations were similar during periods 0.81, P= 0.45, 0.75, respectively). CONCLUSION Amoxiclav anticoagulation without infection.
sci-hub.se 参考文章(19)
Claire Larramendy-Gozalo, Jue Quin Yang, Celine Verstuyft, Laurent Bodin, Liliane Dubert, Yong Zhang, Chundi Xu, Lian Fan, Patrice Jaillon, Laurent Becquemont, Genetic polymorphism of vitamin K epoxide reductase (VKORC1) 1173C>T in a Chinese and a Caucasian population. Basic & Clinical Pharmacology & Toxicology. ,vol. 98, pp. 611- 613 ,(2006) , 10.1111/J.1742-7843.2006.PTO_440.X
Fernie Penning-van Beest, Joëlle Erkens, Karl-Uwe Petersen, Hans Rudolf Koelz, Ron Herings, Main comedications associated with major bleeding during anticoagulant therapy with coumarins. European Journal of Clinical Pharmacology. ,vol. 61, pp. 439- 444 ,(2005) , 10.1007/S00228-005-0947-0
K OBAYASHI, K NAKAMURA, J KAWANA, H OGATA, K HANADA, M KURABAYASHI, A HASEGAWA, K YAMAMOTO, R HORIUCHI, VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients. Clinical Pharmacology & Therapeutics. ,vol. 80, pp. 169- 178 ,(2006) , 10.1016/J.CLPT.2006.04.010
Keiko KAWAMOTO, Akira TOUCHI, Koichi SUGENO, Takashi MATSUBARA, In Vitro Effect of Beta-Lactam Antibiotics and N-Methyl-Tetrazolethiol on Microsomal Vitamin K Epoxide Reductase in Rats Japanese Journal of Pharmacology. ,vol. 47, pp. 169- 178 ,(1988) , 10.1254/JJP.47.169
I. Niopas, S. Toon, L. Aarons, M. Rowland, The effect of cimetidine on the steady-state pharmacokinetics and pharmacodynamics of warfarin in humans. European Journal of Clinical Pharmacology. ,vol. 55, pp. 399- 404 ,(1999) , 10.1007/S002280050647
DAVID M. ANGARAN, VIRGIL C. DIAS, KIT V. AROM, WILLIAM F. NORTHRUP, THOMAS G. KERSTEN, WILLIAM G. LINDSAY, DEMETRE M. NICOLOFF, The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient. Cefamandole, cefazolin, vancomycin. Annals of Surgery. ,vol. 206, pp. 155- 161 ,(1987) , 10.1097/00000658-198708000-00007
Michael D. Freedman, Abiodun G. Olatidoye, Clinically Significant Drug Interactions with the Oral Anticoagulants Drug Safety. ,vol. 10, pp. 381- 394 ,(1994) , 10.2165/00002018-199410050-00003
Hadas D. Fischer, David N. Juurlink, Muhammad M. Mamdani, Alexander Kopp, Andreas Laupacis, Hemorrhage during warfarin therapy associated with cotrimoxazole and other urinary tract anti-infective agents: a population-based study. JAMA Internal Medicine. ,vol. 170, pp. 617- 621 ,(2010) , 10.1001/ARCHINTERNMED.2010.37
Alison E. Aitken, Terrilyn A. Richardson, Edward T. Morgan, REGULATION OF DRUG-METABOLIZING ENZYMES AND TRANSPORTERS IN INFLAMMATION Annual Review of Pharmacology and Toxicology. ,vol. 46, pp. 123- 149 ,(2006) , 10.1146/ANNUREV.PHARMTOX.46.120604.141059
Kenneth Renton, Cytochrome P450 regulation and drug biotransformation during inflammation and infection. Current Drug Metabolism. ,vol. 5, pp. 235- 243 ,(2004) , 10.2174/1389200043335559